Since an IC-LC/MS assay with a generic human IgG4 signature peptide significantly underestimated the tumor distribution of TFP, we proposed the strategy to characterize the pharmacokinetic properties of TFPs in the nonclinical in vivo study by specific LBA or IC-LC/MS to detect the whole TFP molecule including interferon alpha rather than the human IgG4 backbone of TFP. The gene discussed is TRIM39; the disease is neoplasm.